Alan S. Roemer - 27 Apr 2025 Form 4 Insider Report for IN8BIO, INC. (INAB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 May 2025, 20:45:07 UTC
Prior SEC filing
23 Dec 2024
Next SEC filing
12 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jason Minio, Attorney-in-Fact

Key filing fact

Alan S. Roemer filed Form 4 for IN8BIO, INC. (INAB) on 07 May 2025.

Key facts

  • This page summarizes Alan S. Roemer's Form 4 filing for IN8BIO, INC. (INAB).
  • 9 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 07 May 2025, 20:45.

Change

  • Previous filing in this sequence was filed on 23 Dec 2024.
  • Current net transaction value: +$20,922.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643070 Primary reporting owner

Roemer Alan S.

Relationship
Director
Address
C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK
Signature
/s/ Jason Minio, Attorney-in-Fact
Signature date
07 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INAB transaction

Common Stock

Options Exercise

Transaction value
$18,893
Shares
+102,459
Change %
+36%
Price
$0.1844
Shares after
387,489
Date
30 Apr 2025
Ownership
Direct
INAB transaction

Common Stock

Options Exercise

Transaction value
$2,028
Shares
+11,000
Change %
+2.8%
Price
$0.1844
Shares after
398,489
Date
30 Apr 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INAB transaction Derivative

Series A Warrants (right to buy)

Disposed to Issuer

Transaction value
Shares
-102,459
Change %
-100%
Price
Shares after
0
Date
27 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
102,459
Exercise price
$0.4500
Footnotes
F1, F2, F3
INAB transaction Derivative

Series A Warrants (right to buy)

Award

Transaction value
Shares
+102,459
Change %
Price
Shares after
102,459
Date
27 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
102,459
Exercise price
$0.1844
Footnotes
F1, F2
INAB transaction Derivative

Series A Warrants (right to buy)

Options Exercise

Transaction value
$0
Shares
-102,459
Change %
-100%
Price
$0.000000
Shares after
0
Date
30 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
102,459
Exercise price
$0.1844
Footnotes
F2
INAB transaction Derivative

Series B Warrants (right to buy)

Disposed to Issuer

Transaction value
Shares
-102,459
Change %
-100%
Price
Shares after
0
Date
27 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
102,459
Exercise price
$1.50
Footnotes
F2, F3, F4
INAB transaction Derivative

Series B Warrants (right to buy)

Award

Transaction value
Shares
+11,000
Change %
Price
Shares after
11,000
Date
27 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,000
Exercise price
$0.1844
Footnotes
F2, F4
INAB transaction Derivative

Series B Warrants (right to buy)

Options Exercise

Transaction value
$0
Shares
-11,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
30 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,000
Exercise price
$0.1844
Footnotes
F2
INAB transaction Derivative

Series B Warrants (right to buy)

Award

Transaction value
Shares
+91,459
Change %
Price
Shares after
91,459
Date
27 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
91,459
Exercise price
$0.4500
Footnotes
F2, F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.

Footnote F2

Fully vested and exercisable.

Footnote F3

The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock.

Footnote F4

The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date.

Footnote F5

The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .